Dupixent denied by insurance? Appeal and win.
A Dupixent denial is rarely a final answer, it is usually a paperwork gap your plan is daring you to leave unfilled. Because dupilumab is FDA-approved across a spread of type 2 inflammatory conditions, from moderate-to-severe atopic dermatitis and eosinophilic or oral-steroid-dependent asthma to chronic rhinosinusitis with nasal polyps, prurigo nodularis, eosinophilic esophagitis, and COPD with an eosinophilic phenotype, payers lean on indication-specific traps: a topical-corticosteroid or systemic step-therapy requirement in eczema, a documented failure of an inhaled corticosteroid plus controller and an eosinophil count threshold in asthma, or proof of inadequate response to intranasal steroids before polyps. The reversal comes from matching the chart to the exact indication, the correct ICD-10 anchor such as L20.9 for atopic dermatitis or J33.x for nasal polyps, the validated severity measure the label invites (EASI or IGA scores, biologic eosinophil counts, ACQ or exacerbation history), and a clean record of the prior therapies the plan demanded. Build the file around the indication the payer actually disputed, and the medical necessity stops being arguable.
Reviewed by the Apellica Appeals Team · Updated June 2026
Carrier names and logos are trademarks of their respective owners. Apellica is independent and not affiliated with any insurance carrier or carrier's appeal program.
Atopic dermatitis, asthma, and other type-2 inflammatory conditions.
Why Dupixent gets denied
- Step therapy through topical or standard therapy not documented
- Prior-authorization criteria unmet
- Diagnosis or severity not evidenced
- Formulary placement
What a winning appeal includes
- Diagnosis and severity documentation
- Prior therapies and outcomes
- Specialist support
- A letter of medical necessity
How we approach the appeal
Document severity and prior standard-therapy failure, and tie the request to the plan's published criteria.
Dupixent appeal letter template
Copy this Dupixent appeal letter, fill in the brackets, and send it within your deadline. It is built on what overturns IL-4/IL-13 biologic denials.
[Date] [Your name] · Member ID [ID] · Rx claim # [#] [Insurer or PBM] - Appeals Department Re: Appeal of Dupixent denial I am appealing the denial of Dupixent (dupilumab). I request that the denial be overturned and Dupixent approved. 1. The denial. [Insurer] denied Dupixent stating, verbatim: "[paste the exact denial reason from your letter]." 2. Medical necessity. Dupixent is medically necessary for my condition. Document severity and prior standard-therapy failure, and tie the request to the plan's published criteria. 3. Step-therapy or formulary exception (if that was the reason): I have tried and failed [preferred drug(s)], with pharmacy records attached, or the preferred alternative is contraindicated because [reason]. I request a formulary or step-therapy exception. 4. My request. Approve Dupixent within the timeframe required by law. If the denial is upheld, please provide the specific criteria used, the reviewing clinician's credentials, and external-review instructions. Attached: prescriber letter of medical necessity, pharmacy and prior-trial records, and supporting clinical notes. Sincerely, [Your name]
Want it built and filed for you? Use the free generator, or have Apellica do it.
Internal appeals: 30 days pre-service, 60 days post-service, 72 hours urgent. File within 180 days.
$0 upfront. We assess fit first, then build and file the appeal for you.
- · The denial letter and your Explanation of Benefits (EOB)
- · Insurance ID, plan name, and the claim or prior-authorization number
- · Diagnosis with ICD-10 code and the prescriber's clinical notes
- · A record of treatments already tried and how they worked
Appealing a Dupixent denial by insurer
The path depends on who manages your benefit. The most common:
Coverage runs through the pharmacy benefit. Appeal the coverage determination and, when the drug is non-formulary, file a formulary or tier exception with a provider attestation that covered alternatives are unsuitable.
Publishes detailed prior-authorization criteria. A denial usually means a criterion was not documented. Appeal through a coverage review, with a formulary exception for excluded drugs.
Administers many UnitedHealthcare and employer plans. Appeals and exceptions follow the plan's published PA criteria; expedited review exists for urgent cases.
Internal appeal first, then independent external review. Pre-service decisions are generally made within 30 days, urgent within 72 hours.
Internal appeals and external review; pharmacy denials often route through OptumRx criteria.
Independent state plans, so criteria vary. Match the appeal to your specific BCBS plan, internal appeal first, then external review.
Frequently asked questions
Why was my Dupixent denied?
Most often because the plan requires documented failure of standard therapy first, or because severity was not evidenced. Both are addressable on appeal.
Dupixent denied? We fight it for you.
$0 upfront. Two-minute intake. We confirm fit and reply within one business day with the right path for your situation.
Start Your AppealThis page provides general information about appeal strategy. It is not legal or medical advice. Apellica is not a law firm. Outcomes depend on documentation, plan terms, and timing.